This promotional website is for UK Healthcare Professionals involved in the management of haematological malignancies. Adverse event reporting information can be found below.

VENCLYXTO CLL PRESCRIBING INFORMATION

VENCLYXTO GB SUMMARY OF PRODUCT CHARACTERISTICS

VENCLYXTO NI SUMMARY OF PRODUCT CHARACTERISTICS

UK-VNCCLL-230491. Date of preparation: February 2024.

Contact us

Please complete the form below and a member of the VENCLYXTO team will get back to you.

Please fill in your details below only if you are a UK registered healthcare professional and would like to request a meeting with an AbbVie representative.

First name*:

Please enter First name

Last name*:

Please enter Last name

E-mail address*:

E-mail address is not valid

Hospital name:

Please enter Hospital name

Hospital postcode:

Please enter Hospital postcode

Areas of interest

Request a meeting with your local AbbVie representative

I consent to receive AbbVie Ltd communications about its products, services, research, events, programmes and other information, including promotional content, that may be of interest to me using the information I provide. I may withdraw my consent at any time.

Please select one field.

Please refer to the AbbVie privacy notice here for more information on how AbbVie processes your personal data and your data privacy rights.

*Denotes mandatory field

Incorrect. Please try again

UK-VNCCLL-240121. Date of preparation: April 2024.

VENCLYXTO CLL PRESCRIBING INFORMATION
VENCLYXTO AML PRESCRIBING INFORMATION

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk.

Adverse events should also be reported to AbbVie on GBPV@abbvie.com

Contact us

Our therapy areas

Additional info

This website is for UK Healthcare Professionals only

Welcome